Medical University of Vienna in Austria led a multi-centric phase II study with 45 involved centers from all across Europe. Nor-ursodeoxycholic acid was administered to 161 patients in the study.
Here are three points:
1. Michael Trauner, MD, head of the clinical department for gastroenterology and hepatology at the Medical University of Vienna and study researcher, said the patients administered the nor-ursodeoxycholic acid showed significant improvements in liver function test results in all tested dosing.
2. The results were presented at the 2016 International Liver Congress in Barcelona, Spain.
3. Primary sclerosing cholangitis is a liver disease, typically associated with inflammatory bowel disease, with a high risk of colon cancer that affects mainly younger people, especially men between the age of 30 and 40. At present, the disease cannot be cured with medication.
More articles on GI & endoscopy:
4 GI devices receive FDA 510(k) clearance in March
Six steps to reduce taxes on investments
Bank of Montreal Can increases position in EndoChoice by 25.5%: 4 points
